0001437749-23-008072.txt : 20230327
0001437749-23-008072.hdr.sgml : 20230327
20230327183252
ACCESSION NUMBER: 0001437749-23-008072
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230321
FILED AS OF DATE: 20230327
DATE AS OF CHANGE: 20230327
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DARGAN CHARLES K
CENTRAL INDEX KEY: 0001112799
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19709
FILM NUMBER: 23765763
MAIL ADDRESS:
STREET 1: 8055 W. MANCHESTER AVE.
STREET 2: SUITE 405
CITY: PLAYA DEL REY
STATE: CA
ZIP: 90293
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOLARGO, INC.
CENTRAL INDEX KEY: 0000880242
STANDARD INDUSTRIAL CLASSIFICATION: CHEMICALS & ALLIED PRODUCTS [2800]
IRS NUMBER: 650159115
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 14921 CHESTNUT ST.
CITY: WESTMINSTER
STATE: CA
ZIP: 92683
BUSINESS PHONE: 888 400-2863
MAIL ADDRESS:
STREET 1: 14921 CHESTNUT ST.
CITY: WESTMINSTER
STATE: CA
ZIP: 92683
FORMER COMPANY:
FORMER CONFORMED NAME: NUWAY MEDICAL INC
DATE OF NAME CHANGE: 20030205
FORMER COMPANY:
FORMER CONFORMED NAME: NUWAY ENERGY INC
DATE OF NAME CHANGE: 20010815
FORMER COMPANY:
FORMER CONFORMED NAME: LATIN AMERICAN CASINOS INC
DATE OF NAME CHANGE: 19960520
4
1
rdgdoc.xml
FORM 4
X0407
4
2023-03-21
0000880242
BIOLARGO, INC.
BLGO
0001112799
DARGAN CHARLES K
18851 NE 29TH AVENUE
SUITE 700
AVENTURA
FL
3318
1
Chief Financial Officer
0
Option to purchase common stock
0.20
2023-03-21
4
A
0
300000
A
2023-03-21
2033-03-21
Common stock
300000
4331500
D
The Option is exercisable according to its vesting schedule: (i) 25,000 shares vested as of March 21, 2023, and then (ii) in equal monthly installments of 25,000 shares beginning March 31, 2023, so long as the Engagement Extension Agreement dated March 21, 2023, between Reporting Person and Issuer, remains in force and effect.
This Option was issued to the Reporting Person as compensation to serve as Issuer's Chief Financial Officer from February 1, 2023, through January 31, 2024.
Reporting person was notified on March 27, 2023 of the issuer's approval of the March 21, 2023 extension agreement.
/s/ John R. Browning, attorney-in-fact
2023-03-27